Sagimet Biosciences Inc
NASDAQ:SGMT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shofu Inc
TSE:7979
|
JP |
|
S
|
Shandong Link Science and Technology Co Ltd
SZSE:001207
|
CN |
Sagimet Biosciences Inc
Research & Development
Sagimet Biosciences Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sagimet Biosciences Inc
NASDAQ:SGMT
|
Research & Development
-$39.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Sagimet Biosciences Inc
Glance View
Sagimet Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Mateo, California and currently employs 10 full-time employees. The company went IPO on 2023-07-14. Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). In addition to NASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase II clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
See Also
What is Sagimet Biosciences Inc's Research & Development?
Research & Development
-39.1m
USD
Based on the financial report for Dec 31, 2025, Sagimet Biosciences Inc's Research & Development amounts to -39.1m USD.
What is Sagimet Biosciences Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-37%
Over the last year, the Research & Development growth was -2%. The average annual Research & Development growth rates for Sagimet Biosciences Inc have been -16% over the past three years , -37% over the past five years .
